ADA guideline on potentially malignant disorders (2017): biopsy or refer, and not one adjunct earned a routine role

What it says#

An expert panel convened by the ADA Council on Scientific Affairs and the Center for Evidence-Based Dentistry ran a systematic review and wrote recommendations to tell primary care clinicians whether adjuncts are useful as triage tools when evaluating lesions, including potentially malignant disorders, in the oral cavity. It updates the ADA's 2010 recommendations on early diagnosis. The panel searched MEDLINE and Embase via Ovid and the Cochrane Central Register of Controlled Trials for randomized trials and diagnostic test accuracy studies, and used GRADE both to rate certainty and to move from evidence to decision.

The output was one good practice statement and six clinical recommendations. The good practice statement is the exam itself: clinicians should obtain an updated medical, social and dental history and perform an intraoral and extraoral conventional visual and tactile examination in all adult patients. It carries no quality rating and no strength of recommendation, which in GRADE terms means it was too obviously right to need one.

The six recommendations sort by what the clinician finds. For an adult with a lesion of unknown clinical diagnosis that seems innocuous or nonsuspicious, or with symptoms, follow up periodically to determine the need for further evaluation; if the lesion has not resolved and a potentially malignant disorder cannot be ruled out, perform a biopsy or refer to a specialist. For an adult with a lesion suspicious of a potentially malignant or malignant disorder, or with symptoms, perform a biopsy or provide immediate referral. For an adult with no clinically evident lesions or symptoms, no further action is necessary at that time. Each of these is conditional, on low-quality evidence.

Then the three negatives. The panel does not recommend cytologic adjuncts for evaluating potentially malignant disorders in adults with clinically evident, seemingly innocuous or suspicious lesions, with one carve-out: should a patient decline the recommendation for a biopsy or referral, the clinician can use a cytologic adjunct to provide additional lesion assessment, where a positive or atypical result reinforces the need for biopsy and a negative result indicates periodic follow-up, with immediate biopsy or referral if the lesion persists or progresses. The panel does not recommend autofluorescence, tissue reflectance or vital staining adjuncts for the same evaluation, on evidence rated low to very low. And it does not recommend commercially available salivary adjuncts for adults with or without lesions, saying their use should be considered only in the context of research. Every one of the six is a conditional recommendation, which the chairside guide defines as meaning that different choices will be appropriate for different patients and that the clinician must help each patient reach a decision consistent with their values and preferences.

The numbers behind the negatives are in the companion systematic review. It retrieved 7,534 records, of which 9 diagnostic accuracy studies and 10 studies of patients' values and preferences were eligible, alongside 4 existing reviews covering 37 studies. Pooled sensitivity and specificity of the adjuncts ranged from 0.39 to 0.96 for evaluating innocuous lesions and from 0.31 to 0.95 for suspicious ones. Cytologic testing in suspicious lesions was the most accurate adjunct reviewed, at a sensitivity of 0.92 (95% CI 0.86 to 0.98) and specificity of 0.94 (0.88 to 0.99) on low-quality evidence, and the reviewers still flagged a high rate of false positives and serious risk of bias and indirectness, closing with the instruction that clinicians should remain skeptical about the potential benefit of any adjunct in clinical practice.

The guideline's own practical implications go past the devices. The authors urge clinicians to remain alert and take diligent action when they identify a potentially malignant disorder, and emphasize the need for counseling, because patients may delay diagnosis out of anxiety and denial.

Who it applies to#

Adults, and the general dentists, specialists and hygienists who examine them. The pathway starts at the routine, initial or emergency examination, so it reaches the hygiene appointment as much as the doctor's exam. It applies to symptoms too, not only visible lesions: globus sensation, unexplained ear or oropharyngeal pain and hoarseness are in the same funnel.

It does not reach children or adolescents. It does not tell a clinician who is not trained to perform a biopsy to perform one; the guideline says only those trained, that is, dentists, should do so, and referral is the alternative throughout. And it stops at the referral: what the specialist does next, and how a diagnosed cancer is treated, is not in scope.

What changed#

Against the 2010 ADA recommendations this was an update; against the marketing of chairside screening devices it was a correction. Autofluorescence and tissue reflectance devices were being sold to general practices as a way to find what the eye misses, and the panel's answer was that no available adjunct demonstrated sufficient diagnostic accuracy to support routine use as a triage tool. That sentence has done more work in dentistry than the rest of the document.

It has since been overtaken, in parts. The ADA's living oral cancer guideline began replacing it in 2026, one adjunct class at a time, and the ADA now lists the 2017 document on its guideline page under ARCHIVE. The direction of travel has not changed: cytology, vital staining and light-based adjuncts each drew a conditional recommendation against in the new series as well. What changed is the vintage of the evidence and the promise that the recommendations will be revised as new studies appear.

Where the source is#

The document is Lingen and colleagues, Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association, Journal of the American Dental Association 2017, volume 148, issue 10, pages 712 to 727 plus online appendices; the link under the title resolves through the DOI to the publisher's page, which requires a subscription. JADA's site refused automated access in this session, so the recommendation wording, the strengths, the GRADE definitions and the clinical pathway in this entry were read from the ADA's own two-page chairside guide PDF, which is copyright 2017 ADA and may be used, copied and distributed for non-commercial purposes; the guideline's abstract came from PubMed. The companion systematic review, JADA 148(11):797-813, is free in PubMed Central (PMC7366378) and is the source of the accuracy figures. The status of the 2017 guideline as an archived base version comes from the ADA's oral cancer guideline page, which now carries the living guideline first and the 2017 document under a heading reading ARCHIVE.